Basilea Pharmaceutica AG
SIX:BSLN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
32.25
47.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG
Accounts Payable
Basilea Pharmaceutica AG
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Accounts Payable
CHf11.5m
|
CAGR 3-Years
29%
|
CAGR 5-Years
28%
|
CAGR 10-Years
24%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Accounts Payable
$15.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Accounts Payable
CHf1.4m
|
CAGR 3-Years
92%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Accounts Payable
$15.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Molecular Partners AG
SIX:MOLN
|
Accounts Payable
CHf2.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Accounts Payable
CHf2.8m
|
CAGR 3-Years
68%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Accounts Payable?
Accounts Payable
11.5m
CHF
Based on the financial report for Jun 30, 2024, Basilea Pharmaceutica AG's Accounts Payable amounts to 11.5m CHF.
What is Basilea Pharmaceutica AG's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
24%
Over the last year, the Accounts Payable growth was 191%. The average annual Accounts Payable growth rates for Basilea Pharmaceutica AG have been 29% over the past three years , 28% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
